Featured Content

The latest issue of BioProcess International focuses on manufacturing, featuring articles on tissue bioprinting, lipid feed formulations, viral vector manufacturing for gene therapies, biosimilar MAbs, and conjugate characterization. Also includes a special report on Antibody-Drug Conjugates (ADCs).

Read it Now.

Single-Use Supplement

Single-use components and systems are now firmly established in the biopharmaceutical industry. They continue to improve, and their applications are expanding. It seems that for every scientific challenge users discover, suppliers can engineer a solution. New technologies could improve productivity as well as provide the expected single-use benefits. Discover here a disposable valve, a next-generation bioreactor, a continuous culture process, and downstream processing based on single-use technology.

Read it Now.


Figure 1: Immunoglobulin G (IgG) structure consists of four polypeptide chains, including two identical light chains (~25 kDa) and two identical heavy chains (~50 kDa). Each light chain consists of one constant domain (CL) and one variable domain (VL), and each heavy chain consists of three constant domains (CH1, CH2, and CH3) and one variable domain (VH). The Fab is the antigenbinding region containing hypervariable or complementarity-determining regions (CDRs), whereas the Fc region is highly conserved across molecular species. The hinge region contains two disulfide bonds and glycosylation (shown as red dots) at CH2 domain of Fc fragment.

Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 2

Last month, Part 1 of this discussion briefly described the regulatory landscape for developing biosimilar therapeutic monoclonal antibodies (TMAbs). We identified certain specific structural components of TMAb drug substances that warrant particular attention because alterations to them are likely to affect therapeutic safety and effectiveness. Now we conclude by considering whether studies of reference materials can further the development of analytical industry standards to ensure comparability of putative biosimilar TMAbs with innovator TMAbs. We suggest that the time is right…



Special Report on Antibody-Drug Conjugates: Technical Challenges and Opportunities

Among the emerging targeted therapies in biotechnology, antibody–drug conjugates (ADCs) hold a unique position. An ADC consists of a monoclonal antibody (MAb) with affinity to tumor cells, a cytotoxic small-molecule payload, and a linker connecting the two. Together the MAb, conjugation chemistry, and cytotoxin increase the complexity of ADCs several-fold relative to unmodified MAbs — and exponentially relative to chemotherapies. Viewing ADCs as hybrids of antibody- and chemotherapy-based cancer therapies is tempting. That description applies chemically and structurally, but ADCs’…

Figure 2A: Pall Allegro STR 200 bioreactor components

Upstream Processing

Design and Performance of Single-Use, Stirred-Tank Bioreactors

Single-use components and systems have been incorporated into many bioprocesses as an alternative to cleanable, reusable systems. A wide range of publications have detailed the reasons for this trend toward a single-use approach. Justification in many cases comes from process-specific benefits such as increased manufacturing flexibility — especially for contract manufacturing organizations (CMOs) — enhanced sterility assurance, elimination of cleaning, reduced capital investment, faster processing times with increased productivity, faster start-up, and other benefits (1). One critical factor in the…